Four-year clinical and echocardiographic outcomes of the Myval device in mitral, tricuspid, and pulmonary positions
REC: interventional cardiology (English Edition) · 16.11.2026
DOI: 10.24875/recice.m26000632 ↗Kurz gefasst
Fachartikel in der Zeitschrift REC: interventional cardiology (English Edition), online erschienen am 16.11.2026. Verfasst von Akash Jain und 22 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and objectives: Transcatheter implantation of balloon-expandable valves in non-aortic positions represents a growing off-label strategy for valve-in-valve and valve-in-ring procedures in high-risk patients. We assessed 4-year clinical outcomes and echocardiographic performance of the transcatheter heart valve Myval THV implanted in the mitral, tricuspid, and pulmonary positions.
Methods
This retrospective multicenter study included a total of 50 patients (mitral n = 33; tricuspid n = 13; pulmonary n = 4) treated across 11 centers, with clinical follow-up extending to 4 years and echocardiographic assessment of surviving patients.
Results
Technical successs was achieved in 96.9% of mitral cases (1 procedural death) and in 100% of tricuspid and pulmonary cases. At 1 year, death had occurred in 2/33 (6.1%) mitral patients and in none of the tricuspid or pulmonary patients. At 4 years, death had occurred in 4/33 (12.1%) mitral, 2/13 (15.3%) tricuspid, and 0/4 pulmonary patients; stroke occurred in 0/33, 1/13 (7.6%), and 0/4 patients, respectively. Mean transvalvular gradients at 4 years were 8.5 ± 3.3 mmHg (mitral), 3.8 ± 1.6 mmHg (tricuspid), and 12.7 ± 9.9 mmHg (pulmonary). No moderate or greater bioprosthetic regurgitation was observed at 4-year echocardiographic assessment, and no valve reinterventions were recorded during follow-up.
Conclusions
In this multicenter cohort, off-label use of the Myval THV in non-aortic positions demonstrated adequate midterm clinical outcomes and sustained echocardiographic performance up to 4 years. These preliminary findings support the feasibility of this transcatheter approach in selected patients but require further prospective validation.
Zitieren
APA
Jain, A., Montorfano, M., Freeman, P., Jose, J., Costa, M. M. D., Abdurashid, M., Gunasekaran, S., Nissen, H., Martín, P., Seth, A., Stambuk, K., García-Gómez, M., Murillo, M. R., Pensotti, F., Jorgensen, M. D., Zúñiga, M., Aristizabal, C., Cortés, C., Vallinas-Hernández, S., …, & Amat-Santos, I. J. (2026). Four-year clinical and echocardiographic outcomes of the Myval device in mitral, tricuspid, and pulmonary positions. REC: interventional cardiology (English Edition). https://doi.org/10.24875/recice.m26000632
Vancouver
Jain A, Montorfano M, Freeman P, Jose J, Costa MMD, Abdurashid M, et al. Four-year clinical and echocardiographic outcomes of the Myval device in mitral, tricuspid, and pulmonary positions. REC: interventional cardiology (English Edition). 2026. doi:10.24875/recice.m26000632
BibTeX
@article{Jain2026,
author = {Jain, Akash and Montorfano, Matteo and Freeman, Phillip and Jose, John and Costa, Marcio Montenegro da and Abdurashid, Mussayev and Gunasekaran, Sengottuvelu and Nissen, Henrik and Martín, Pedro and Seth, Ashok and Stambuk, Kresimir and García-Gómez, Mario and Murillo, Marcelo Rodríguez and Pensotti, Filippo and Jorgensen, Mathias D. and Zúñiga, Mauricio and Aristizabal, Cristhian and Cortés, Carlos and Vallinas-Hernández, Silvia and Carrasco-Moraleja, Manuel and Román, J. Alberto San and and and Amat-Santos, Ignacio J.},
title = {Four-year clinical and echocardiographic outcomes of the Myval device in mitral, tricuspid, and pulmonary positions},
journal = {REC: interventional cardiology (English Edition)},
year = {2026},
doi = {10.24875/recice.m26000632}
}
EUVIMED